Phase III IMpower131 Study Showed Genentechs TECENTRIQ Atezolizumab Plus Chemotherapy Carboplatin and ABRAXANE Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the Phase III IMpower131 study met its coprimary endpoint of progressionfree survival PFS and demonstrated that the combination of TECENTRIQÂ atezoli...